Eli Lilly and Company (India) on Tuesday said it has received approval from national drug regulator CDSCO for a drug to treat Alzheimer's disease.

The company has received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for donanemab (350 mg/20 mL), administered every four weeks via intravenous infusion, for the treatment of Alzheimer's disease in adults with early symptomatic stages.

This includes individuals with mild cognitive impairment and those in the mild dementia stage of the disease, the drug maker said in a statement.

"The approval of donanemab marks a significant milestone in our mission to address the urgent needs of people living with Alzheimer's disease in India," said Winselow Tucker, president and general manager, Lilly India.

By off

See Full Page